IP Library Granted Patent US 7,514,464
Granted Patent B2
US 7,514,464 · App. 11/153,103 · Granted Apr 7, 2009

Substituted arylpyrazoles

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,514,464
App. No.
11/153,103
Granted
Apr 7, 2009
Kind
B2
Abstract

This invention relates to a combination product comprising a compound of formula I wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 9 are as described herein, and one or more further biologically active compounds as described herein, particularly anti-parasitic agents.

Claims (57)

1. A combination product comprising a compound of formula (I):

wherein:

R 1 is CF 3 , OCF 2 H, OCF 3 , —SCF 3 , —SOCF 3 , —SO 2 CF 3 , or SF 5 ;

R 2 is H, fluoro, or C 1-4 alkyl optionally substituted by 1 to 5 halogen atoms independently selected from chloro and fluoro;

R 3 , R 4 , R 5 , and R 6 are independently selected from H, Cl, F, or C 1-4 alkyl optionally substituted by 1 to 5 halogen groups independently selected from chloro and fluoro;

R 7 is Cl or fluoro;

X is CR 8 where R 8 is Cl or fluoro; and

R 9 is NR a R b ;

R a is selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C(O)OC 1-6 alkyl and C 1-6 alkanoyl, wherein each of the above groups may include one or more optional substituents where chemically possible independently selected from halo, phenyl, hydroxy, —C(O)OH, —C(O)O C 1-6 alkyl, C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, amino, C 1-6 alkyl amino and di C 1-6 alkyl amino;

R b is selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkanoyl and C(O)OC 1-6 alkyl, wherein each of the above groups may include one or more optional substituents where chemically possible independently selected from, halo, phenyl, hydroxy, —COOH, —C(O)O C 1-6 alkyl, C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, amino, C 1-6 alkyl amino and di C 1-6 alkyl amino;

or a pharmaceutically acceptable salt or prodrug thereof;

with the proviso that at least one of R 2 , R 3 , R 4 , R 5 , or R 6 is fluoro, with one or more other biologically active compounds.

2. The combination of claim 1 , wherein R 1 is CF 3 or SF 5 .

3. The combination of claim 1 , wherein R 2 is F, CF 3 or CHF 2 .

4. The combination of claim 1 , wherein R 3 and R 4 both represent fluoro and R 5 and R 6 represent hydrogen.

5. The combination of claim 1 , wherein R 2 is CF 3 , R 3 and R 4 both represent fluoro and R 5 and R 6 represent hydrogen.

6. The combination of claim 1 , wherein X is CR 8 and R 7 and R 8 are both chloro.

7. The combination of claim 1 , wherein R 9 is selected from NH 2 , C 1-6 alkoxycarbonylamino, with optional substitution on the alkyl group by one or more fluoro groups, di-C 1-6 alkylamino and het, C 1-6 alkylamino, with optional substitution on the alkyl group by one or more fluoro groups, C 3-8 cycloalkyl, phenyl and het.

8. The combination of claim 1 , wherein R 9 is NH 2 .

9. The combination of claim 1 , wherein the compound of formula (I) is selected from:

5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(1,2,2-trifluorocyclopropyl)-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(pentafluorocyclopropyl)-1H-pyrazole-3-carbonitrile;

5-amino-4-(2,2-dichloro-1-fluorocyclopropyl)-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-(pentafluorocyclopropyl)-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-(1,2,2-trifluorocyclopropyl)-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[1-(difluoromethyl)-2,2-difluorocyclopropyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(2,2-difluorocyclopropyl)-1H-pyrazole-3-carbonitrile;

5-amino-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1-[2,6-difluoro-4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[1-(difluoromethyl)-2,2-difluorocyclopropyl]-1H-pyrazole-3-carbonitrile;

5-amino-4-{1-[chloro(fluoro)methyl]-2,2-difluorocyclopropyl}-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[1-(difluoromethyl)-2,2,3,3-tetrafluorocyclopropyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[2,2,3,3-tetrafluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazole-3-carbonitrile;

1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-5-(methylamino)-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-4-[1-(difluoromethyl)-2,2,3,3-tetrafluorocyclopropyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-4-[1-(difluoromethyl)-2,2-difluorocyclopropyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[2,2-difluoro-1-(fluoromethyl)cyclopropyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(2,2-difluoro-1-methylcyclopropyl)-1H-pyrazole-3-carbonitrile;

5-amino-1-{2,6-dichloro-4-[(trifluoromethyl)thio]phenyl}-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazole-3-carbonitrile;

ethyl 3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazol-5-ylcarbamate;

1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-5-(2-oxo-1,3-oxazolidin-3-yl)-1H-pyrazole-3-carbonitrile;

2-(dimethylamino)ethyl 3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazol-5-ylcarbamate;

2,2,2-trifluoroethyl 3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazol-5-ylcarbamate;

5-amino-1-{2,6-dichloro-4-[(trifluoromethyl)sulfonyl]phenyl}-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-(difluoromethoxy)phenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazole-3-carbonitrile;

5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[1-(difluoromethyl)-2,2,3,3-tetrafluorocyclopropyl]-1H-pyrazole-3-carbonitrile;

Isopropyl 3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazol-5-ylcarbamate; and

5-amino-4-{1-[chloro(difluoro)methyl]-2,2-difluorocyclopropyl}-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonitrile, or a pharmaceutically acceptable salt thereof.

10. The combination of claim 1 , wherein the combination comprises a compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more other anti-parasitic agents.

11. The combination of claim 10 , wherein the one or more other anti-parasitic agents are selected from ivermectin, avermectin, abamectin, emamectin, eprinomectin, doramectin, selamectin, moxidectin, nemadectin, albendazole, cambendazole, fenbendazole, flubendazole, mebendazole, oxfendazole, oxibendazole, parbendazole, tetramisole, levamisole, pyrantel pamoate, oxantel, morantel, triclabendazole, praziquantel, epsiprantel, fipronil, lufenuron, ecdysone, tebufenozide and imidacloprid.

12. A pharmaceutical composition comprising a compound of formula (I) of claim 1 , or a pharmaceutically acceptable salt thereof, one or more further biologically active compounds, and a pharmaceutically suitable excipient.

13. A compound of claim 1 which is 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazole-3-carbonitrile, or a pharmaceutically acceptable salt thereof.

14. A compound of claim 1 which is 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]4-(1,2,2-trifluorocyclopropyl)-1H-pyrazole-3-carbonitrile, or a pharmaceutically acceptable salt thereof.

15. A compound of claim 1 which is 5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazole-3-carbonitrile, or a pharmaceutically acceptable salt thereof.

16. A compound of claim 1 which is 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(pentafluorocyclopropyl)-1H-pyrazole-3-carbonitrile, or a pharmaceutically acceptable salt thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: ZOETIS LLC
To: ZOETIS SERVICES LLC
Reel/Frame 035651/0817 →
CHANGE OF NAME Recorded Mar 28, 2013
From: AH USA 42 LLC
To: ZOETIS LLC
Reel/Frame 030119/0866 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2013
From: PFIZER INC.
To: AH USA 42 LLC
Reel/Frame 029609/0336 →
CONSENT FROM PFIZER LTD Recorded Sep 27, 2012
From: PFIZER LTD
To: PFIZER INC
Reel/Frame 029045/0694 →